Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.41 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802345 | 0.87 | LMNA (0.48) | SMN1; SMN2KDM4EPTGDR2LMNAHTT | |
| SCHEMBL2393564 | 0.86 | ICMT (0.47) | SMN1; SMN2KDM4EPTGER2 | |
| SCHEMBL9890781 | 0.82 | TP53 (0.42) | SMN1; SMN2PTGER2LMNAHTT | |
| SCHEMBL9105295 | 0.79 | PTGER1 (0.57) | SMN1; SMN2KDM4EPTGER2PTGDR2DCLRE1B | |
| SCHEMBL9890679 | 0.78 | KDM4E (0.49) | SMN1; SMN2KDM4EPTGER2PTGDR2DCLRE1B | |
| SCHEMBL503912 | 0.77 | AKR1B1 (0.56) | KDM4EAKR1B1 | |
| SCHEMBL9890671 | 0.76 | PTGDR2 (0.50) | SMN1; SMN2KDM4EPTGER2PTGDR2DCLRE1B | |
| SCHEMBL9890666 | 0.76 | PTGDR2 (0.50) | SMN1; SMN2KDM4EPTGER2PTGDR2DCLRE1B | |
| Hydrochloric Acid SCHEMBL1372001 | 0.75 | AKR1B1 (0.54) | KDM4EAKR1B1 | |
| SCHEMBL2393626 | 0.74 | RAB9A (0.46) | SMN1; SMN2KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SMN1; SMN2 2980/4885KDM4E 829/4885PTGER2 1191/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SMN1; SMN2 2980/4885KDM4E 829/4885PTGER2 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.